Zobrazeno 1 - 10
of 30
pro vyhledávání: '"D. Liden"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Value in Health. 21:S60-S61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d173b5bbd9151591b8b60546252cf60
https://doi.org/10.1016/j.jval.2018.09.356
https://doi.org/10.1016/j.jval.2018.09.356
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:46-46
IntroductionThe relationship between heath technology assessment (HTA) recommendations and drug prices has received little attention in the published literature. We consider whether target population sizes estimated as part of positive HTA decisions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ff704de474a0d2f7a6fb5953b0d83a5
https://doi.org/10.1017/s026646231900206x
https://doi.org/10.1017/s026646231900206x
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:2-3
INTRODUCTION:As of July 2016, funding from England's Cancer Drugs Fund (CDF) is dispensed based on the results of National Institute for Health and Care Excellence (NICE) technology appraisal guidances instead of independent CDF appraisals (1). As pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbe736f5704fa9a963b27411ab1a1101
https://doi.org/10.1017/s0266462317001143
https://doi.org/10.1017/s0266462317001143
Publikováno v:
Glycobiology. 22:160-169
Glycan-binding proteins are commonly used as analytical reagents to detect the levels of specific glycan structures in biological samples. A detailed knowledge of the specificities of glycan-binding proteins is required for properly interpreting thei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2930242d7568a693fadf7e8e17991f82
https://doi.org/10.1093/glycob/cwr128
https://doi.org/10.1093/glycob/cwr128
Publikováno v:
Value in Health. 21:S61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e486604439326fa4d647a6c01295fa61
https://doi.org/10.1016/j.jval.2018.09.357
https://doi.org/10.1016/j.jval.2018.09.357
Publikováno v:
Value in Health. 18(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d50fd5b5397dded4fabbc1eca5d1091
Publikováno v:
Value in Health. 18(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c18948cb7bd33ea647507cde01760d
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:156-156
INTRODUCTION:As of July 2016, funding from England's Cancer Drugs Fund (CDF) is dispensed based on the results of National Institute for Health and Care Excellence (NICE) technology appraisal guidances instead of independent CDF appraisals (1). NICE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e0b1e5d4b0a89813ba1e06d3392ceed
https://doi.org/10.1017/s0266462317003130
https://doi.org/10.1017/s0266462317003130
Publikováno v:
Value in Health. 18(3):A95-A96
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cd7666f2fac5d7bafcf4543949e65ba